中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study

文献类型：期刊论文

作者Song, Zhengbo7,8; Lv, Dongqing9; Chen, Shiqing5; Huang, Jianhui1; Wang, Liping6; Xu, Shuguang2; Chen, Huafei3; Wang, Guoqiang5; Lin, Quan4
刊名FRONTIERS IN ONCOLOGY
出版日期2021-05-07
卷号11
ISSN号2234-943X
关键词non-small cell lung cancer (NSCLC) HER2 afatinib efficacy resistance
DOI10.3389/fonc.2021.657283
通讯作者Song, Zhengbo(songzhengbo83@163.com) ; Lin, Quan(lquan007@163.com)
英文摘要Background Non-small cell lung cancer (NSCLC) patients with HER2 mutations and amplification may benefit from HER2-targeted therapy, including afatinib. However, the data regarding the clinical activity of afatinib in Chinese patients with NSCLC harboring HER2 alterations are limited. Patients and methods We retrospectively included metastatic NSCLC patients harboring HER2 alterations who treated with afatinib. The clinical outcomes included overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). The genomic profiling data after progression on afatinib were analyzed. Results We included 54 patients harboring HER2 mutations and 12 patients harboring HER2 amplification. The ORR was 24% (95% CI, 16-36%), the median PFS was 3.3 months (95% CI, 2.2-4.4), and the median OS was 13.9 months (95% CI, 11.4-16.5). Patients with HER2 exon 20 mutations had numerically worse ORR (17% vs 42%), shorter PFS (2.6 vs 5.8 months, HR, 2.5; 95% CI, 1.2-5.5; P = 0.015) and OS (12.9 vs 33.3 months, HR, 4.4; 95% CI, 1.3-14.8; P = 0.009) than patients with other mutations. For HER2-amplified patients, the ORR was 33% (95% CI, 14-61%), the median PFS was 3.3 months (95% CI, 2.6-4.0), and the median OS was 13.4 months (95% CI, 0-27.6). The most frequently mutated genes in afatinib-resistant patients were TP53 (44%) and EGFR (33%). Three afatinib-resistant patients harbored secondary HER2 alterations. Conclusions Our results suggest that afatinib has a promising anti-tumor activity in patients with NSCLC harboring HER2 alterations. To our knowledge, this is the largest retrospective study about the clinical activity of afatinib in NSCLC patients with HER2 alterations.
WOS研究方向Oncology
语种英语
出版者FRONTIERS MEDIA SA
WOS记录号WOS:000652576900001
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/122677]  
专题中国科学院合肥物质科学研究院
通讯作者Song, Zhengbo; Lin, Quan
作者单位1.Lishui Ctr Hosp, Dept Med Oncol, Lishui, Peoples R China
2.Lihuili Eastern Hosp, Ningbo Med Ctr, Dept Resp Dis, Ningbo, Zhejiang, Peoples R China
3.Rongjun Hosp, Dept Thorac Dis Ctr, Jiaxing, Peoples R China
4.Wenzhou Med Univ, Dept Pulm Med, Affiliated Hosp 1, Wenzhou, Peoples R China
5.3D Med Inc, Med Dept, Shanghai, Peoples R China
6.Baotou Canc Hosp, Dept Med Oncol, Baotou, Peoples R China
7.Univ Chinese Acad Sci, Dept Clin Trail, Canc Hosp, Zhejiang Canc Hos, Hangzhou, Peoples R China
8.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China
9.Taizhou Hosp, Dept Resp Dis, Taizhou, Peoples R China
推荐引用方式
GB/T 7714		 Song, Zhengbo,Lv, Dongqing,Chen, Shiqing,et al. Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study[J]. FRONTIERS IN ONCOLOGY,2021,11.
APA Song, Zhengbo.,Lv, Dongqing.,Chen, Shiqing.,Huang, Jianhui.,Wang, Liping.,...&Lin, Quan.(2021).Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study.FRONTIERS IN ONCOLOGY,11.
MLA Song, Zhengbo,et al."Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study".FRONTIERS IN ONCOLOGY 11(2021).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。